Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target

Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new VELDONA® Pet cytoprotein supplement products.

Related Keywords

Taiwan ,San Diego ,California ,United States ,Robin Yang ,Colorado State University ,Company Form ,Agricultural Technology Research Institute ,Exchange Commission ,Ainos Inc ,Linkedin ,Pet Shiny ,Pet Slim ,Pet Lohas ,Pet Soothing ,Pet Cytoprotein ,Hsien Tsai ,Aino Chairman ,Chief Executive Officer ,Volatile Organic Compounds ,Ainos Flora ,Securities Litigation Reform Act ,Annual Report ,